Friday , 21 February 2025
0

No products in the cart.

Worldwide News Worldwide News
0

No products in the cart.

Home Health Aiming to Outdo Rivals in Severe Asthma, Upstream Bio Upsizes IPO to $225M
Health

Aiming to Outdo Rivals in Severe Asthma, Upstream Bio Upsizes IPO to $225M

October 11, 20241 Mins read48 Views
Aiming to Outdo Rivals in Severe Asthma, Upstream Bio Upsizes IPO to $225M

Upstream Bio will use its IPO haul to continue clinical testing of verekitug, which it contends be a better treatment option for severe asthma compared to a commercialized Amgen and AstraZeneca drug. CAMP4 Therapeutics and Ceribell also priced IPOs to join the public markets.

The post Aiming to Outdo Rivals in Severe Asthma, Upstream Bio Upsizes IPO to $225M appeared first on MedCity News.

Previous post “Ready to climb that mountain” – Arsenal fans will love what their ex-midfielder has predicted

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles

Health

This year’s ViVE conference was full of announcements — from acquisitions to...

ByFebruary 21, 2025
Health

Do you think hormones cause mood swings in women only?It is not...

ByFebruary 20, 2025

PEPFAR, the U.S. global HIV/AIDS program, is - for the first time...

ByFebruary 20, 2025

In Feedspot’s 2025 rankings, Healthcare Economist was once again ranked in the...

ByFebruary 20, 2025

Abous us

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis

Subscribe Now

    Subscribe to our mailing list to receives daily updates direct to your inbox!
    © Copyright 2022 Jellywp. All rights reserved powered by Jellywp.com